InvestSMART
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Managed Funds
  5. Global X S&P Biotech ETF - Managed fund profile

Global X S&P Biotech ETF - Managed Fund

Fund Objective
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
Fund Strategy
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Fund Performance Comparison

Relative Fund Performance vs {{ fund.benchmark.peers.peerCount }} peers using {{ fund.benchmark.name }} as their benchmark.

{{ fund.name }}
Peers
Benchmark ({{ fund.benchmark.name }})
{{ fund.model.name }}
The performance of the peers is calculated as the total of the performance for each time period for all the funds in the peer group, divided by the number of funds in the peer group.
grow your money
Grow your money, not your fees
It's fees rather than returns that make the biggest difference to your investment's compounding returns.
Free Fees Report
investing
Investing made simple
Our professionally-tailored investment portfolios consistently beat most of our peers.
Free investor guide
Grow your money, not your fees
It's fees rather than returns that make the biggest difference to your investment's compounding returns. Free Fees Report
Investing made simple
Our professionally-tailored investment portfolios consistently beat most of our peers. Free investor guide

Fees Comparison

{{ fund.mer | number:2 }}
% p.a.
{{ fund.name }}
{{ modelPortfolio.mer * 100 | number:2 }}
% p.a.
{{ modelPortfolio.name }}
{{ fund.benchmark.peers.mer * 100 | number:2 }}
% p.a.
Average of peers ({{ fund.benchmark.peers.peerCount }})
NOTE: Fee data has been provided by Morningstar, it may not include all costs being charged on your investment such as platform and adviser fees. You should check your fund manager or adviser statements to find out the exact fees you are being charged. Peers are funds that use the same benchmark in the Morningstar database.
Upsell Banner

Fund performance

  1M 3M 6M 1Y p.a. 2Y p.a. 3Y p.a. 5Y p.a. 10Y p.a.
Total return -3.63% 11.25% 28.48% 27.73% 10.17% -6.6% 2.44% -%
Growth return -3.63% 11.25% 28.48% 27.73% 10.14% -9.57% -2.03% -%
Income return 0% 0% 0% 0% 0.03% 2.97% 4.47% -%
Market index (MSCI World Ex Australia NR AUD)
Total return 3.02% 14.06% 20.11% 28.72% 15.87% 14.43% -% 13.43%
As at 31 Mar 2024. Returns for periods greater than 1 year are annualised. All figures are percentages.

Asset Allocation

Global X S&P Biotech ETF
Australian Equities
100%
International Equities
0%
Cash
0%
Property
0%
Fixed Interest
0%
Alternatives
0%
Average Allocation of Peers
Australian Equities
3.41%
International Equities
91.78%
Cash
2.96%
Property
1.83%
Fixed Interest
-0.04%
Alternatives
0.06%

General Information

Fund Details
Type Description
Global X S&P Biotech ETF
ANZ ETFS Management (AUS) Ltd
Equity World Other
Not Rated
Investment Fund
8 Nov 2018
$39.28 million (as at 12 Apr 2024)
$42.5 (as at 30 Aug 2023)
$40 (as at 30 Aug 2023)
Open
Offer information
Type Description
Indirect Cost Ratio (ICR) 0.45% (as at 30 Jun 2023)
Performance fee (not included in ICR) 0
Minimum initial investment $500.00

Top 10 holdings (as at 15 Apr 2024)

Holding (as at 15 Apr 2024) Type % of Portfolio
Alpine Immune Sciences Inc Equity 1.80%
Login now to view the complete list of holdings.

FAQs about the Global X S&P Biotech ETF

The objective of the Global X S&P Biotech ETF managed fund is The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

The strategy of the Global X S&P Biotech ETF managed fund is The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

The APIR code of the Global X S&P Biotech ETF managed fund is .

Global X S&P Biotech ETF’s total return last month was -3.63%. This was made up of a growth return of -3.63% and an income return of 0%. These returns were calculated as at 31 Mar 2024.

Global X S&P Biotech ETF’s total return for the last three months was 11.25%. This was made up of a growth return of 11.25% and an income return of 0%%. These returns were calculated as at 31 Mar 2024.

Global X S&P Biotech ETF’s one-year total return is 27.73%. This was made up of a growth return of 27.73% and an income return of 0%. These returns were calculated as at 31 Mar 2024.

Global X S&P Biotech ETF’s one-year total return is -6.6%. This was made up of a growth return of -9.57% and an income return of 2.97%. These returns were calculated as at 31 Mar 2024.

The asset allocation of the Global X S&P Biotech ETF managed fund is :

Australian Equities
100%
International Equities
0%
Cash
0%
Property
0%
Fixed Interest
0%
Alternatives
0%

The Responsible Entity for the Global X S&P Biotech ETF managed fund is ANZ ETFS Management (AUS) Ltd.

The Global X S&P Biotech ETF managed fund belongs to the Equity World Other sector/asset class.

As at 12 Apr 2024, the size of the Global X S&P Biotech ETF managed fund was $39.28 million.

The Global X S&P Biotech ETF managed fund has an inception date of 8 Nov 2018.

The current entry price of the Global X S&P Biotech ETF managed fund is $42.5 per unit and the current exit price is $40 per unit (as at 30 Aug 2023).

The current exit price of the Global X S&P Biotech ETF managed fund is $40 per unit and the current entry price is $42.5 per unit (as at 30 Aug 2023).

The minimum initial investment amount for the Global X S&P Biotech ETF managed fund is $500.

Fund data sourced from Morningstar. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only. Whilst every care has been taken in producing these numbers, neither Morningstar nor InvestSMART can make any guarantees around the complete accuracy of these figures. Should you decide to change investments, please read all relevant disclosure documents including the Product Disclosure Statements and if required, you may consider speaking to a financial professional for further guidance. A tax event may be realised as a result of switching investments. Past performance is not a reliable indicator of future performance.